What is the Historical Analysis of the Rare Kidney Diseases Market Size?
The rare kidney diseases market has seen considerable growth due to a variety of factors.
•In the recent past, the market size for rare kidney diseases has experienced a swift growth. The market, which will be worth $2.76 billion in 2024, is projected to increase to a value of $3.06 billion in 2025, growing at a compound annual growth rate (CAGR) of 10.6%.
Factors contributing to this growth during the historical period include better disease recognition, the designation of orphan drugs, increased patient advocacy, awareness initiatives, and international research collaborations.
What is the Forecasted Growth of the Rare Kidney Diseases Market Size?
The rare kidney diseases market is expected to maintain its strong growth trajectory in upcoming years.
• Anticipated swift expansion is on the horizon for the rare kidney diseases market in the coming years. Projections indicate growth to $4.49 billion by 2029, with a compound annual growth rate (CAGR) of 10.1%.
Factors driving this surge during the forecast period include advancements in gene therapies, amplified funding for rare disease research, increased alliances among stakeholders, and international programs tackling rare diseases. Key trends for the forecast period encompass a focus on patients, the use of real-world proof and data analysis, regulatory changes, the advent of telemedicine and home-based patient monitoring, as well as global health drives.
What Are The Primary Growth Drivers In The Rare Kidney Diseases Market?
The rare kidney disease market is projected to grow, fueled by government initiatives and investments in kidney disease. These directives and financial support from the government are directed towards selected entities with projects or ideas that can enhance public services and the economy. The aim is to improve disease surveillance and the quality of life for individuals suffering from various kidney diseases. This is achieved by utilizing a broad public health approach in collaboration with other public health agencies and national organizations. For example, in July 2022, The United States House Committee on Appropriations, an affiliate of the House of Representatives, initiated numerous proposals to advocate for kidney health. These include an allocation of $8.5 million for the Centers for Disease Control and Prevention's (CDC) chronic kidney disease program, aimed at expediting activities for promoting awareness, diagnosis, and treatment of regular kidney disease. Additionally, a $1 million investment was made in the National Living Donor Assistance Center to enhance living donation, raising the total investment in research and advancement to $8 million. Thus, government initiatives and support for kidney diseases are powering the expansion of the rare kidney disease market.
What Is The Segmentation Of The Global Rare Kidney Diseases Market?
The rare kidney diseases market covered in this report is segmented –
1) By Target Indication: IgA Nephropathy, Lupus Nephritis, Focal Segmental Glomerular Sclerosis, Membranous Nephropathy, C3 Glomerulopathy, Other Target Indications
2) By Type Of Molecule: Small Molecules, Biologics
3) By Route Of administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration
Subsegments:
1) By IgA Nephropathy: Immunosuppressive Therapy, Supportive Care And Symptomatic Management
2) By Lupus Nephritis: Corticosteroids, Antimalarial Agents, Biologics
3) By Focal Segmental Glomerular Sclerosis (FSGS): Corticosteroids, Angiotensin Receptor Blockers (ARBs), Other Immunosuppressive Agents
4) By Membranous Nephropathy: Corticosteroids, Immunosuppressive Therapy, Monoclonal Antibodies
5) By C3 Glomerulopathy: Complement Inhibitors, Supportive Care, Immunosuppressive Therapies
6) By Other Target Indications: Alport Syndrome, Thin Basement Membrane Nephropathy, Other Rare Kidney Disorders
Pre-Book The Rare Kidney Diseases Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Shaping The Rare Kidney Diseases Market Landscape?
The rare kidney disease market is seeing a significant rise in product innovation, as one of the key trends, with leading players focusing on the development of novel products to enhance their standing in the market. A case in point is STADA Arzneimittel AG, a Germany-based firm specializing in generics, specialty pharma, and over-the-counter healthcare products. The company launched Kinpeygo (budesonide) in September 2022, the first ever medicine authorized in the European Union for treating immunoglobulin A nephropathy (IgAN) - a distinct type of rare kidney disease. These adjusted-release budesonide capsules mark the first and only EU approved treatment for primary IgAN. This is a rare auto-immune kidney disease that advances over time, and presents a significant unmet medical need, with 25%-30% of patients ultimately requiring challenging options like dialysis or kidney transplants due to terminal kidney insufficiency.
Who Are the Key Players in the Rare Kidney Diseases Market?
Major companies operating in the rare kidney diseases market include:
• Merck & Co. Inc.
• Novartis AG
• Sanofi S.A
• AstraZeneca plc
• Otsuka Pharmaceutical Co Ltd.
• Alexion Pharmaceuticals Inc.
• Horizon Therapeutics plc.
• Recordati S.p.A.
• Amicus Therapeutics Inc.
• Akebia Therapeutics Inc.
• Travere Therapeutics
• FibroGen Inc.
• Aurinia Pharmaceuticals Inc.
• Calliditas Therapeutics AB
• Apellis Pharmaceuticals Inc.
• Protalix Biotherapeutics Inc.
• ChemoCentryx Inc.
• Omeros Corporation
• Celtaxsys Inc.
• Corbus Pharmaceuticals Holdings Inc.
• Chinook Therapeutics Inc.
• OxThera AB
• Advicenne Pharma SA
• Reata Pharmaceuticals Inc.
• Savara Inc.
What are the Regional Insights into the Rare Kidney Diseases Market?
North America was the leading region in the rare kidney disease market in 2024. The regions covered in the rare kidney diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
